Koenig Franz, Krasnozhon Sergey, Bornkamp Bjoern, Bretz Frank, Glimm Ekkehard, Graf Alexandra, Xi Dong
Center for Medical Data Science, Medical University of Vienna, Vienna, Austria.
Novartis Pharma AG, Basel, Switzerland.
Stat Med. 2025 May;44(10-12):e70124. doi: 10.1002/sim.70124.
The MCP-Mod approach by Bretz et al. is commonly applied for dose-response testing and estimation in clinical trials. The MCP part of MCP-Mod was originally developed to detect a dose-response signal using a multiple contrast test, but it is not appropriate to make a specific claim that the drug has a positive effect at an individual dose. In this paper, we extend the MCP-Mod approach to obtain confirmatory p-values for detecting a dose-response signal as well as for the pairwise comparisons of the individual doses against placebo. We apply the closed test principle from Marcus et al. to the optimal contrast tests based on a candidate set of plausible dose-response shapes available at the planning stage of a clinical trial. We show that the contrast coefficients have to be optimized under suitable constraints to guarantee strong Type 1 error rate control at a pre-specified significance level. Motivated by a recent clinical trial, we evaluate the operating characteristics of the proposed methods in a comprehensive simulation study.
Bretz等人提出的MCP-Mod方法通常用于临床试验中的剂量反应测试和估计。MCP-Mod中的MCP部分最初是为了使用多重对比检验来检测剂量反应信号而开发的,但声称药物在某个特定剂量下具有积极效果并不合适。在本文中,我们扩展了MCP-Mod方法,以获得用于检测剂量反应信号以及将各个剂量与安慰剂进行两两比较的验证性p值。我们将Marcus等人的封闭检验原则应用于基于临床试验规划阶段可用的一组合理剂量反应形状候选集的最优对比检验。我们表明,对比系数必须在适当的约束下进行优化,以确保在预先指定的显著性水平上严格控制一类错误率。受最近一项临床试验的启发,我们在一项全面的模拟研究中评估了所提出方法的操作特性。